TransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. raised its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 23.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 78,002 shares of the company's stock after purchasing an additional 14,578 shares during the quarter. Oppenheimer & Co. Inc. owned 0.23% of TransMedics Group worth $5,248,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TMDX. Cambridge Investment Research Advisors Inc. lifted its position in shares of TransMedics Group by 65.9% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 11,692 shares of the company's stock worth $787,000 after purchasing an additional 4,643 shares during the last quarter. Abundance Wealth Counselors grew its holdings in shares of TransMedics Group by 22.0% in the first quarter. Abundance Wealth Counselors now owns 6,747 shares of the company's stock worth $454,000 after purchasing an additional 1,218 shares during the last quarter. Cornerstone Wealth Management LLC increased its stake in TransMedics Group by 68.5% in the 1st quarter. Cornerstone Wealth Management LLC now owns 6,247 shares of the company's stock worth $420,000 after buying an additional 2,540 shares during the period. Janney Montgomery Scott LLC lifted its holdings in TransMedics Group by 129.9% during the 1st quarter. Janney Montgomery Scott LLC now owns 8,799 shares of the company's stock valued at $592,000 after buying an additional 4,972 shares in the last quarter. Finally, Campbell Newman Asset Management Inc. lifted its holdings in TransMedics Group by 1.4% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock valued at $782,000 after buying an additional 166 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Insider Activity

In other news, Director David Weill sold 732 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director now directly owns 12,134 shares of the company's stock, valued at approximately $1,503,159.92. This represents a 5.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward M. Basile sold 6,000 shares of the stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the sale, the director now owns 732 shares of the company's stock, valued at approximately $84,641.16. This represents a 89.13% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,418 shares of company stock worth $1,512,613. Corporate insiders own 7.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TMDX. Piper Sandler restated an "overweight" rating and issued a $145.00 target price (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Oppenheimer raised their price target on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Finally, Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $127.33.

TransMedics Group Stock Down 3.1%

Shares of NASDAQ:TMDX traded down $4.06 on Wednesday, reaching $128.58. The company had a trading volume of 711,280 shares, compared to its average volume of 1,365,325. The firm has a market capitalization of $4.35 billion, a PE ratio of 94.54 and a beta of 2.10. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The firm's 50 day simple moving average is $115.95 and its 200-day simple moving average is $85.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The company had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. During the same quarter last year, the company earned $0.35 earnings per share. The firm's revenue for the quarter was up 48.2% compared to the same quarter last year. As a group, analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.